Development of acetylated HDD kit for preparation of 188Re-HDD/lipiodol

Applied Radiation and Isotopes

Volumn 65, Issue 1, 2007, Pages 64-69

  Lee, Yun Sang ^a,b,c   Min Jeong, Jae ^a,c   Joo Kim, Young ^a,c   Soo Chang, Young ^a   Jeong Lee, Hak ^a,c   Son, Miwon ^d   Woo Lee, Jung ^e   Sik Yoon, Heung ^e   Jun Kang, Won ^a   Soo Lee, Dong ^a   Chung, June Key ^a   Chul Lee, Myung ^a,c   Suh, Young Ger ^b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Dong A Pharmaceutical Company   (South Korea)

^e Leadgen Company Limited   (South Korea)

Author keywords

188Re; HDD; Lipiodol; Liver cancer therapy

Indexed keywords

BIODIVERSITY; BIOLOGICAL ORGANS; BIOMEDICAL ENGINEERING; PATIENT TREATMENT;

LIPIODOL SOLUTION; LIVER CANCER THERAPY; RADIOLABELING EFFICIENCY; SULFHYDRYL GROUPS;

ONCOLOGY;

2,2,9,9 TETRAMETHYL 4 HEXADECYL 4,7 DIAZA 1,10 DECANE DIETHIOACETATE RE 188; 4 HEXADECYL 2,2,9,9 TETRAMETHYL 4,7 DIAZA 1,10 DECANEDITHIOL RE 188; RADIOPHARMACEUTICAL AGENT; RHENIUM 188; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACETYLATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG STABILITY; DRUG SYNTHESIS; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACETYLATION; ANIMALS; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; IODIZED OIL; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; RADIOPHARMACEUTICALS; REAGENT KITS, DIAGNOSTIC; TISSUE DISTRIBUTION;

EID: 33846176073     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2006.07.008     Document Type: Article

References (15)

1. 3 as a hippuran replacement. J. Nucl. Med. 27 (1986) 111-116
2. 188Re-labeled radiopharmaceuticals: an overview of promising results from initial clinical trials. Cancer Biother. Radiopharm. 18 (2003) 707-717
3. 188Re-TDD, for the treatment of liver cancer. Nucl. Med. Biol. 28 (2001) 197-204
4. Knapp Jr. F.F., Beets A.L., Guhlke S., Zamora P.O., Bender H., Palmedo H., and Biersack H.J. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. Anticancer Res. 17 (1997) 1783-1795
5. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a Phase I clinical trial. J. Nucl. Med. 46 (2005) 60-66
6. 188Re-HDD/lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis. J. Nucl. Med. 46 (2005) 1326-1332
7. 188Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl. Med. Commun. 23 (2002) 237-242
8. Lever S.Z., Burns H.D., Kervitsky T.M., Goldfarb H.W., Woo D.V., et al. Design, preparation, and biodistribution of a technetium-99 m triaminedithiol complex to assess regional cerebral blood flow. J. Nucl. Med. 26 (1985) 1287-1294
9. Park C.H., Suh J.H., and Yoo H.S. Evaluation of intrahepatic I-131 ethiodol on a patient with hepatocellular carcinoma. Clin. Nucl. Med. 11 (1986) 514-517
10. Park C.H., Yoo H.S., Lee J.T., and Kim D.I. Iodine-131-labeled lipiodol retention within hepatic cavernous hemangioma. Radiology 163 (1987) 283-284
11. Sundram F.X., Jeong J.M., Zanzonico P., Bernal P., Chau T., et al. Trans-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma. World J. Nucl. Med. 1 (2002) 5-11
12. Sundram F., Chau T.C.M., Onkhuudai P., Bernal P., and Padhy A.K. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable hepatocellulat carcinoma. Eur. J. Nucl. Med. 31 (2004) 250-257
13. Wang S.-J., Lin W.-Y., Chen M.-N., Hsieh B.-T., Shen L.-H., et al. Biodistribution of rhenium-188 lipiodol infused via the hepatic artery of rats with hepatic tumors. Eur. J. Nucl. Med. 23 (1996) 13-17
14. 188Re for hepatic tumor therapy. Appl. Radiat. Isot. 47 (1996) 267-271
15. Yoo H.S., Suh J.H., Lee J.T., Kim D.I., Park C.Y., et al. Therapeutic feasibility study and clinical trial of intrahepatic I-131-lipiodol on patients with hepatocellular carcinoma. Korean J. Nucl. Med. 20 (1986) 61-71